A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age

NCT01100606 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis
Exocrine Pancreatic Insufficiency

Interventions

DRUG: EUR-1008 (APT-1008)
DRUG: EUR-1008 (APT-1008)

Sponsor

Forest Laboratories